




## Provider Bulletin 20-19 October 13, 2020



# Clinical Guidelines and Related Provider Requirements

Community Behavioral Health (CBH) has adopted Clinical Practice Guidelines (CPGs) to outline best practices for the treatment of specific disorders or certain populations. These guidelines outline best practices for the such treatments and will be used by CBH to assess the quality of care provided to CBH members. As such, providers are advised to review and, where appropriate, implement these best practices in their care. CPGs apply to all clinical settings where members are seen with these disorders. CPGs should be used in conjunction with any level-of-care-specific performance standards as well as all other required CBH, NIAC, state, and federal regulations and standards.

CBH is issuing a newly developed guideline for treatment of adults with Major Depressive Disorder (MDD). The most recent version of all CPGs can be found in Section 7.2., “Clinical Guidelines,” of the [CBH Provider Manual](#).

To ensure alignment and best practices, CBH recommends that providers review the CPGs and make any necessary updates or revisions to provider policies and procedures.

Adherence to the CPGs will be assessed through CBH monitoring and oversight, including Quality, Clinical, and Compliance Department protocols. Additionally, components may be reviewed as part of NIAC initial and recredentialing reviews. To assess quality of care and align with state and regulatory requirements, CBH will also be utilizing several specific metrics for the CPG, which are detailed in the table below.

Clinical Guidelines	Quality Metrics
<p><i>Clinical Guidelines for Treatment of Adults with Major Depressive Disorder</i></p>	<ol style="list-style-type: none"> <li>1. The HEDIS AMM Measure for Antidepressant Medication Management is used to assess the percentage of members 18 years of age and older who were effectively treated with antidepressant medication during the acute and continuation phases.               <ul style="list-style-type: none"> <li>• Effective acute phase treatment is defined as percentage of members 18 years of age and older who had a diagnosis of MDD and who were treated with and remained on an antidepressant medication for at least 84 days (12 weeks).</li> <li>• Effective continuation phase treatment is defined as percentage of members 18 years of age and older who had a diagnosis of MDD and who were treated with and remained on an antidepressant medication for at least 180 days (6 months).</li> </ul> </li> <li>2. The HEDIS FUH Measure for Follow-up After Hospitalization for Mental Illness will be adapted to capture follow-up after</li> </ol>

	<p>hospitalization due to severe symptoms of MDD including suicidal ideation or attempted suicide. The FUH measure is 2-part and includes:</p> <ul style="list-style-type: none"><li>• 7-day follow-up: An outpatient visit, intensive outpatient visit, or partial hospitalization with a mental health practitioner, within seven days of discharge.</li><li>• 30-day follow-up: An outpatient visit, intensive outpatient visit, or partial hospitalization with a mental health practitioner, within thirty days of discharge</li></ul>
--	---

These requirements take effect Tuesday, November 10, 2020. Please direct questions to [CBH.PharmacyInitiatives@phila.gov](mailto:CBH.PharmacyInitiatives@phila.gov).